Masami Tanaka

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 24, 2026

T lymphopenia in multiple sclerosis patients treated with ofatumumab: Even with consideration for CD3 + CD20+ cells.

T lymphopenia in multiple sclerosis patients treated with ofatumumab: Even with consideration for CD3 + CD20+ cells.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: June 17, 2025

Current trends in multiple sclerosis/neuromyelitis optica spectrum disorder therapy: considerations for domestic administration and personalized therapy

Current trends in multiple sclerosis/neuromyelitis optica spectrum disorder therapy: considerations for domestic administration and personalized therapy

Journal: Rinsho shinkeigaku = Clinical neurology

Published: April 29, 2025

Perioperative management of patients treated with satralizumab

Perioperative management of patients treated with satralizumab

Journal: Rinsho shinkeigaku = Clinical neurology

Published: March 24, 2024

HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data.

HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data.

Journal: Scientific reports

Published: March 27, 2020

Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod.

Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod.

Journal: Journal of neuroinflammation

Published: February 29, 2020

Neurotropic Properties of AAV-PHP.B Are Shared among Diverse Inbred Strains of Mice.

Neurotropic Properties of AAV-PHP.B Are Shared among Diverse Inbred Strains of Mice.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: March 08, 2019

Therapeutic drug monitoring of natalizumab.

Therapeutic drug monitoring of natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 29, 2018

Treatment for paraneoplastic neuromyelitis optica spectrum disorder (NMOsd): Probable effects of tocilizumab for both cancer and NMOsd.

Treatment for paraneoplastic neuromyelitis optica spectrum disorder (NMOsd): Probable effects of tocilizumab for both cancer and NMOsd.

Journal: Multiple sclerosis and related disorders

Published: November 12, 2017

Dimethyl Fumarate in Multiple Sclerosis

Dimethyl Fumarate in Multiple Sclerosis

Journal: Brain and nerve = Shinkei kenkyu no shinpo

Published: September 14, 2017

Intermittent drug holidays in fingolimod therapy for multiple sclerosis.

Intermittent drug holidays in fingolimod therapy for multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 26, 2017

Spatio-temporal and dynamic regulation of neurofascin alternative splicing in mouse cerebellar neurons.

Spatio-temporal and dynamic regulation of neurofascin alternative splicing in mouse cerebellar neurons.

Journal: Scientific reports

Published: April 13, 2017

Showing 1-12 of 40

Last Updated: 09/26/2026